Detalles de la búsqueda
1.
Discovery of structural diverse reversible BTK inhibitors utilized to develop a novel in vivo CD69 and CD86 PK/PD mouse model.
Bioorg Med Chem Lett;
80: 129108, 2023 01 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36538993
2.
BTK inhibition limits B-cell-T-cell interaction through modulation of B-cell metabolism: implications for multiple sclerosis therapy.
Acta Neuropathol;
143(4): 505-521, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35303161
3.
Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors.
Bioorg Med Chem Lett;
60: 128549, 2022 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35041943
4.
Utilizing structure based drug design and metabolic soft spot identification to optimize the in vitro potency and in vivo pharmacokinetic properties leading to the discovery of novel reversible Bruton's tyrosine kinase inhibitors.
Bioorg Med Chem;
44: 116275, 2021 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34314938
5.
Utilization of Cyclic Amides as Masked Aldehyde Equivalents in Reductive Amination Reactions.
J Org Chem;
84(12): 7936-7949, 2019 06 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-31117567
6.
Optimization of novel reversible Bruton's tyrosine kinase inhibitors identified using Tethering-fragment-based screens.
Bioorg Med Chem;
27(13): 2905-2913, 2019 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31138459
7.
Corrigendum to "Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors" [Bioorg. Med. Chem. Lett. 60 (2022) 128549].
Bioorg Med Chem Lett;
72: 128856, 2022 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35728998
8.
The Discovery of 7-Isopropoxy-2-(1-methyl-2-oxabicyclo[2.1.1]hexan-4-yl)-N-(6-methylpyrazolo[1,5-a]pyrimidin-3-yl)imidazo[1,2-a]pyrimidine-6-carboxamide (BIO-7488), a Potent, Selective, and CNS-Penetrant IRAK4 Inhibitor for the Treatment of Ischemic Stroke.
J Med Chem;
67(6): 4676-4690, 2024 Mar 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-38467640
9.
Discovery and Preclinical Characterization of BIIB129, a Covalent, Selective, and Brain-Penetrant BTK Inhibitor for the Treatment of Multiple Sclerosis.
J Med Chem;
67(10): 8122-8140, 2024 May 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38712838
10.
Discovery of Phospholipase D Inhibitors with Improved Drug-like Properties and Central Nervous System Penetrance.
ACS Med Chem Lett;
13(4): 665-673, 2022 Apr 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-35450377
11.
Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis.
J Med Chem;
65(2): 1206-1224, 2022 01 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-34734694
12.
Next-generation Bruton's tyrosine kinase inhibitor BIIB091 selectively and potently inhibits B cell and Fc receptor signaling and downstream functions in B cells and myeloid cells.
Clin Transl Immunology;
10(6): e1295, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34141433
13.
Discovery of BIIB068: A Selective, Potent, Reversible Bruton's Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases.
J Med Chem;
63(21): 12526-12541, 2020 11 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32696648
14.
ROMPgel-supported triphenylphosphine with potential application in parallel synthesis.
Org Lett;
4(11): 1975-7, 2002 May 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-12027661
15.
Parallel synthesis of terminal alkynes using a ROMPgel-supported ethyl 1-diazo-2-oxopropylphosphonate.
Org Lett;
6(5): 835-7, 2004 Mar 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-14986987
16.
Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases.
Protein Sci;
19(3): 429-39, 2010 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-20052711
17.
Identification of individual protein-ligand NOEs in the limit of intermediate exchange.
J Biomol NMR;
36(1): 1-11, 2006 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-16964534
Resultados
1 -
17
de 17
1
Próxima >
>>